P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) – Pipeline Review, H2 2016’, provides in depth analysis on P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted pipeline therapeutics.

The report provides comprehensive information on the P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)

The report reviews P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics and enlists all their major and minor projects

The report assesses P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Momenta Pharmaceuticals, Inc.

Pfizer Inc.

Selexys Pharmaceuticals Corporation

Tumorend, LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) Overview 7

Therapeutics Development 8

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Products under Development by Stage of Development 8

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Products under Development by Therapy Area 9

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Products under Development by Indication 10

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Products under Development by Companies 13

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Companies Involved in Therapeutics Development 21

Momenta Pharmaceuticals, Inc. 21

Pfizer Inc. 22

Selexys Pharmaceuticals Corporation 23

Tumorend, LLC 24

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Drug Profiles 25

GM-0111 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

necuparanib - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

pentosan polysulfate sodium - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

rivipansel sodium - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

SelG-1 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Inhibit P and L Selectins for Inflammation and Oncology - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules to Inhibit P-Selectin, L-Selectin and PMN Proteases for Oncology - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Dormant Projects 42

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Discontinued Products 44

P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Featured News & Press Releases 45

Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis 45

Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 45

May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 46

Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 47

Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 47

Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel 48

Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology 48

Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel 49

Jun 23, 2015: Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease 50

Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 51

May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 52

Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015 52

Mar 03, 2015: GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease 52

Dec 09, 2014: GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist Rivipansel at 56th ASH Annual Meeting 54

Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 21

Pipeline by Pfizer Inc., H2 2016 22

Pipeline by Selexys Pharmaceuticals Corporation, H2 2016 23

Pipeline by Tumorend, LLC, H2 2016 24

Dormant Projects, H2 2016 42

Dormant Projects (Contd..1), H2 2016 43

Discontinued Products, H2 2016 44

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports